JP2021512161A5 - - Google Patents

Info

Publication number
JP2021512161A5
JP2021512161A5 JP2020562086A JP2020562086A JP2021512161A5 JP 2021512161 A5 JP2021512161 A5 JP 2021512161A5 JP 2020562086 A JP2020562086 A JP 2020562086A JP 2020562086 A JP2020562086 A JP 2020562086A JP 2021512161 A5 JP2021512161 A5 JP 2021512161A5
Authority
JP
Japan
Prior art keywords
hydrogen
pharmaceutically acceptable
solvate
compound according
acceptable salt
Prior art date
Application number
JP2020562086A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021512161A (ja
JPWO2019148161A5 (https=
JP7337395B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/015547 external-priority patent/WO2019148161A1/en
Publication of JP2021512161A publication Critical patent/JP2021512161A/ja
Publication of JPWO2019148161A5 publication Critical patent/JPWO2019148161A5/ja
Publication of JP2021512161A5 publication Critical patent/JP2021512161A5/ja
Application granted granted Critical
Publication of JP7337395B2 publication Critical patent/JP7337395B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020562086A 2018-01-29 2019-01-29 Ｃｄｋ４およびｃｄｋ６阻害剤としての２ｈ－インダゾール誘導体およびその治療上の使用 Active JP7337395B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862623516P 2018-01-29 2018-01-29
US62/623,516 2018-01-29
PCT/US2019/015547 WO2019148161A1 (en) 2018-01-29 2019-01-29 2h-indazole derivatives as cdk4 and cdk6 inhibitors and therapeutic uses thereof

Publications (4)

Publication Number Publication Date
JP2021512161A JP2021512161A (ja) 2021-05-13
JPWO2019148161A5 JPWO2019148161A5 (https=) 2022-01-17
JP2021512161A5 true JP2021512161A5 (https=) 2022-01-17
JP7337395B2 JP7337395B2 (ja) 2023-09-04

Family

ID=67394794

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020562086A Active JP7337395B2 (ja) 2018-01-29 2019-01-29 Ｃｄｋ４およびｃｄｋ６阻害剤としての２ｈ－インダゾール誘導体およびその治療上の使用

Country Status (15)

Country Link
US (1) US11352341B2 (https=)
EP (1) EP3746072B1 (https=)
JP (1) JP7337395B2 (https=)
KR (1) KR20200115583A (https=)
CN (1) CN111989099A (https=)
AU (1) AU2019211491B2 (https=)
BR (1) BR112020015405A2 (https=)
CA (1) CA3088381A1 (https=)
EA (1) EA202091450A1 (https=)
IL (1) IL275948A (https=)
MX (1) MX2020007959A (https=)
PH (1) PH12020551155A1 (https=)
SG (1) SG11202006748RA (https=)
TW (1) TW201940166A (https=)
WO (1) WO2019148161A1 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019018584A1 (en) 2017-07-18 2019-01-24 GiraFpharma LLC HETEROCYCLIC COMPOUNDS AS ADENOSINE ANTAGONISTS
EP3654982A4 (en) 2017-07-18 2021-04-14 Nuvation Bio Inc. 1,8-NAPHTHYRIDINONE COMPOUNDS AND THEIR USES
WO2019161224A1 (en) 2018-02-15 2019-08-22 GiraFpharma LLC Heterocyclic compounds as kinase inhibitors
PL3806898T3 (pl) * 2018-06-18 2026-02-23 UCB Biopharma SRL Antagonista gremlin-1 do zastosowania w leczeniu nowotworu
EP3911324A4 (en) 2019-01-18 2022-08-17 Nuvation Bio Inc. 1,8-NAPHTHYRIDINONE COMPOUNDS AND THEIR USES
EP3911323A4 (en) 2019-01-18 2022-11-16 Nuvation Bio Inc. HETEROCYCLIC COMPOUNDS AS ADENOSINE ANTAGONISTS
AU2020215684B2 (en) * 2019-01-29 2025-08-21 Beta Pharma, Inc. 2h-indazole derivatives as therapeutic agents for brain cancers and brain metastases
MX2021013531A (es) 2019-05-05 2022-02-11 Qilu Regor Therapeutics Inc Inhibidores de cdk.
EP4159728A4 (en) * 2020-06-22 2024-06-26 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. MANUFACTURING PROCESS FOR CDK4/6 INHIBITOR
US20230416271A1 (en) * 2020-11-26 2023-12-28 Chengdu Cynogen Bio-Pharmaceutical Technology Co., Ltd. Heteroarylquinazoline compounds as protein kinase inhibitors
WO2022113003A1 (en) 2020-11-27 2022-06-02 Rhizen Pharmaceuticals Ag Cdk inhibitors
WO2022149057A1 (en) 2021-01-05 2022-07-14 Rhizen Pharmaceuticals Ag Cdk inhibitors

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2251677T3 (es) 2002-01-22 2006-05-01 Warner-Lambert Company Llc 2-(piridin-2-ilamino)-pirido(2,3-d)pirimidin-7-onas.
ATE412650T1 (de) 2003-07-11 2008-11-15 Warner Lambert Co Isethionat salz eines selektiven cdk4 inhibitors
CN1956982A (zh) 2004-05-21 2007-05-02 万有制药株式会社 具有氨基噻唑骨架的Cdk4、6选择性抑制剂
TWI398252B (zh) 2006-05-26 2013-06-11 諾華公司 吡咯并嘧啶化合物及其用途
US9259399B2 (en) 2007-11-07 2016-02-16 Cornell University Targeting CDK4 and CDK6 in cancer therapy
ES2522346T3 (es) 2008-08-22 2014-11-14 Novartis Ag Compuestos de pirrolopirimidina como inhibidores de CDK
JO2885B1 (en) 2008-12-22 2015-03-15 ايلي ليلي اند كومباني Protein kinase inhibitors
US9796701B2 (en) 2013-12-31 2017-10-24 Xuanzhu Pharma Co., Ltd. Kinase inhibitor and use thereof
MY187555A (en) 2014-07-24 2021-09-29 Beta Pharma Inc 2-h-indazole derivatives as cyclin-dependent kinase (cdk) inhibitors and therapeutic uses thereof
US9969719B2 (en) 2015-03-11 2018-05-15 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Substituted 2-hydrogen-pyrazole derivative serving as anticancer drug
CN107286134B (zh) 2016-04-11 2019-04-12 上海勋和医药科技有限公司 2，4-二取代嘧啶衍生物作为cdk抑制剂及其应用

Similar Documents

Publication Publication Date Title
JP2021512161A5 (https=)
CN115803326A (zh) Egfr抑制剂及其制备方法与在药学上的应用
JPWO2019148161A5 (https=)
CN115803325A (zh) 一种egfr抑制剂及其制备方法和应用
JP2020500862A5 (https=)
JP2023525656A (ja) Ｅｇｆｒ阻害剤、その調製方法及びその使用
CN110582483A (zh) 含邻氨基杂芳环炔基的化合物及其制备方法和用途
JP2018517686A5 (https=)
JP2020531447A5 (https=)
JP5901634B2 (ja) キナゾリン化合物及びその使用方法
JP2018536634A5 (https=)
JP2018516917A5 (https=)
JP2005516067A5 (https=)
CN102395576A (zh) 调控jak激酶的喹唑啉衍生物和其使用方法
JP2009513703A5 (https=)
CN103124729A (zh) 作为Axl抑制剂的药物活性化合物
RU2011152973A (ru) Индуцирующие апоптоз средства для лечения злокачественной опухоли и иммунных и аутоиммунных заболеваний
JP2019518079A5 (https=)
JP2015508103A5 (https=)
JP2005525322A5 (https=)
CN116113416A (zh) 四环类衍生物、其制备方法和其医药上的用途
CN117062819A (zh) 多环化合物及其用途
JP2013528215A5 (https=)
JP2013544794A5 (https=)
JP2006528199A5 (https=)